...
首页> 外文期刊>Journal of Chemistry >Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs
【24h】

Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs

机译:N- [1-(((3,4-二苯基噻唑-2(3H)-亚烷基)氨基)甲基)环戊基]乙酰胺衍生物的合成和评价,用于治疗属于MAO的疾病

获取原文

摘要

A series of N-[1-(((3,4-diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide derivatives (4a-4i) were synthesized in good yield and assayed for their inhibitory potency against monoamine oxidase (MAO) isoforms. Structures of newly synthesized compounds were characterized by IR, 1H-NMR, 13C-NMR, and mass spectroscopic methods. The inhibitory activity of compounds (4a-4i) against hMAO-A and hMAO-B enzymes was elucidated by using in vitro fluorometric method using Amplex Red® reagent. In the hMAO-A inhibition assay, compounds 4a, 4b, 4c, and 4i exhibited similar activity with standard drug moclobemide (IC50 = 6.061 ± 0.262 µM) with IC50 values of 7.06 ± 0.18 µM, 6.56 ± 0.20 µM, 6.78 ± 0.15 µM, and 7.09 ± 0.17 µM, respectively. According to hMAO-B inhibition results, compounds 4a, 4b, and 4c displayed significant activity with IC50 values of 0.42 ± 0.012 µM, 0.36 ± 0.014 µM, and 0.69 ± 0.020 µM, respectively. In the wake of all these results, it was understood that compound 4b was found to be the most potent derivative in the series against both isoforms and selective as MAO-B inhibitor. The cytotoxicity test was performed for compounds 4a, 4b, and 4c, and it was found that these compounds were noncytotoxic at the concentration of their IC50 values. Also, enzyme kinetic and docking studies of compound 4b were performed against MAO-B. It was observed that 4b showed a reversible and noncompetitive inhibition type. The important binding modes of this compound with active site of hMAO-B were shown owing to in silico studies.
机译:以高收率合成了一系列N- [1-((((3,4-二苯基噻唑-2(3H)-亚烷基)氨基)甲基)环戊基]乙酰胺衍生物(4a-4i),并测定了其对单胺的抑制作用氧化酶(MAO)同工型。通过IR,1 H-NMR,13 C-NMR和质谱法表征新合成的化合物的结构。通过使用AmplexRed®试剂的体外荧光法,阐明了化合物(4a-4i)对hMAO-A和hMAO-B酶的抑制活性。在hMAO-A抑制试验中,化合物4a,4b,4c和4i与标准药物莫洛贝米(IC50 = 6.061±0.262μM)表现出相似的活性,IC50值分别为7.06±0.18μM,6.56±0.20μM,6.78±0.15μM ,分别为7.09±0.17μm。根据hMAO-B的抑制结果,化合物4a,4b和4c显示出显着的活性,IC 50值分别为0.42±0.011μM,0.36±0.014μM和0.69±0.020μM。在所有这些结果之后,可以理解,发现化合物4b是该系列中对抗同工型最有效的衍生物,并且选择性地作为MAO-B抑制剂。对化合物4a,4b和4c进行了细胞毒性测试,发现这些化合物在其IC 50值的浓度下无细胞毒性。而且,针对MAO-B进行了化合物4b的酶动力学和对接研究。观察到4b显示出可逆和非竞争性抑制类型。由于计算机研究,显示了该化合物与hMAO-B的活性位点的重要结合方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号